QUEBEC CITY, March 23, 2005 – Mr. Renaud Beauchesne, President and CEO of Advitech
Inc. (TSX-V: AVI) will be a presenter at BioMatch 2005, which will be held on March 31, 2005,
at the Fairmount-Queen Elizabeth in Montreal. Mr. Beauchesne’s presentation is scheduled to
begin at 15:40. An update will be provided on XP-828L’s development program, including the
on-going clinical study for psoriasis and the pre-clinical study for inflammatory bowel diseases.
Mr. Beauchesne will also comment on discussions initiated to secure marketing alliances for the
BioMatch 2005 is presented as part of BIOMEDEX 2005, the pre-eminent life science industry
conference-exhibition in Canada, which will be held next March 30 and 31 at the Fairmont-The
Queen Elizabeth Hotel. Organized by BIOQuebec and the Association of Health Technologies
Industry (AITS), the event strives to be the ultimate meeting place for the key players working in
the areas of biotechnology, health technology, pharmaceuticals, venture capital, research and
development.will feature presentations by the CEOs from 40 emerging life science companies
from across Canada and the US.
Advitech is a biotechnology company specializing in the development of bioactive ingredients
from dairy proteins. Its key focus areas are in the fields of immunology and inflammation. Its
main platform, XP-828L, is a growth factor complex used as an oral product for mild to moderate
psoriasis and also for other immune-mediated chronic inflammatory diseases. Advitech’s
common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of
common shares outstanding is 54,799,818.
- 30 -
This press release contains forward-looking statements which reflect the Company's current expectations
regarding future events. The forward-looking statements involve risks and uncertainties. Actual results
could differ materially from those projected herein. The reader is cautioned not to rely on these forwardlooking
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.